Huajun Liang

Huajun Liang

Auto-generated profile, based on publicly available information

Huajun Liang

Department of Diagnostic Radiology and Nuclear Medicine , 12264 University of Maryland School of Medicine , Baltimore , MD , USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
LCLinda Chang
Linda Chang
MRMeghann C. Ryan
Meghann C. Ryan
HLHuajun Liang
Huajun Liang
XZXin Zhang
Xin Zhang
ECEric Cunningham
Eric Cunningham
TEThomas M. Ernst
Thomas M. Ernst
Background and Objectives: Post-COVID condition (PCC) is common and often involves neuropsychiatric symptoms. This study aimed to use blood-oxygenation-level-dependent functional MRI (BOLD-fMRI) to assess whether participants with PCC had abnormal brain activation during working memory (WM), and whether the abnormal brain activation could predict cognitive performance, motor function or psychiatric symptoms. Methods: The PCC participants had documented COVID-19 at least 6 weeks prior to enrollment. Healthy control participants had no prior history of COVID-19 and negative tests for SARS-CoV-2. Participants were assessed using three NIH-Toolbox (NIHTB) batteries for Cognition (NIHTB-CB), Emotion (NIHTB-EB) and Motor function (NIHTB-MB), as well as selected tests from the Patient-Reported Outcomes Measurement Information System (PROMIS). Each had BOLD-fMRI at 3 Tesla, during WM (N-back) tasks with increasing attentional/WM load. Results: 169 participants were screened; 50 fulfilled the study criteria and had complete and usable datasets for this cross-sectional cohort study. 29 PCC participants were diagnosed with COVID-19 242±156 days earlier, had similar ages (42±12 vs. 41±12 years), gender proportion (65% vs. 57%), racial/ethnic distribution, handedness, education, and socioeconomic status, as the 21 uninfected healthy controls. Despite the high prevalence of memory (79%) and concentration (93%) complaints, the PCC group had similar and normal performance on the NIHTB-CB as the controls. However, PCC participants had greater brain activation than the controls across the network (p-FDR-corrected=0.003, T-max=4.17), with greater activation in the right superior frontal gyrus (p=0.009, Cohen’s-d=0.81, 95%CI [0.15-1.46]) but lesser deactivation in the default mode regions (p=0.001, d=1.03, 95%CI [0.61-1.99]). Compared to controls, PCC participants also had poorer dexterity and endurance on the NIHTB-MB, higher T-scores for negative affect and perceived stress, but lower T-scores for psychological well-being on the NIHTB-EB, as well as more pain symptoms and poorer mental and physical health on measures from PROMIS. Greater brain activation also predicted poorer scores on measures that were abnormal on the NIHTB-EB. Discussion: PCC participants with neuropsychiatric symptoms demonstrated compensatory neural processes with greater usage of alternate brain regions, and reorganized networks, to maintain normal performance during WM tasks. BOLD-fMRI was sensitive for detecting brain abnormalities that correlated with various quantitative neuropsychiatric symptoms.

27 September 2014 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
QHQiaoting Huang
Qiaoting Huang
JLJiwu Liao
Jiwu Liao
YLYaping Liu
Yaping Liu
HLHuajun Liang
Huajun Liang
PMPing Ma
Ping Ma
JPJiyang Pan
Jiyang Pan

15 August 2022 in NeuroImmune Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
MSMuhammad G. Saleh
Muhammad G. Saleh
LCLinda Chang
Linda Chang
HLHuajun Liang
Huajun Liang
MRMeghann C. Ryan
Meghann C. Ryan
ECEric Cunningham
Eric Cunningham
TEThomas Ernst
Thomas Ernst
Objectives: Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is associated with lower plasma glutathione (GSH) levels due to oxidative stress. However, plasma levels may not reflect brain GSH levels. Individuals with post-acute sequelae of COVID-19 (PASC) have a higher prevalence of cognitive fatigue, which might be related to altered brain γ-aminobutyric-acid (GABA) levels. Hence, our study aims to measure the brain GSH and GABA levels in PASC. Methods: 29 PASC participants and 24 uninfected controls were recruited for this study. Each was evaluated with detailed neuropsychiatric assessments and an edited proton MRS (Hadamard Encoding and Reconstruction of Mega-Edited Spectroscopy, HERMES) method to measure GABA and GSH concentrations in predominantly grey matter (GM) and predominantly white matter (WM) brain frontal voxels. Results: PASC participants were 219 ± 137 days since their COVID-19 diagnosis. Nine individuals with PASC were hospitalized. Compared to controls, individuals with PASC had similar levels of GABA in both brain regions, but lower GSH and greater age-related GSH decline in the frontal GM region. Conclusions: The lower-than-normal frontal GM GSH level in participants with PASC suggest that they have ongoing oxidative stress in the brain, and that older individuals may be even more vulnerable to oxidative stress.

10 August 2023 in Addiction
Verified
Journal Article
Closed access
HWHannah A. Wang
Hannah A. Wang
HLHua‐Jun Liang
Hua‐Jun Liang
TEThomas M. Ernst
Thomas M. Ernst
HNHelenna Nakama
Helenna Nakama
ECEric Cunningham
Eric Cunningham
LCLinda Chang
Linda Chang

17 November 2025 in NeuroImmune Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
MRMeghann Ryan
Meghann Ryan
JTJared Thomas
Jared Thomas
JWJeremy Wang
Jeremy Wang
HLHuajun Liang
Huajun Liang
ECEric Cunningham
Eric Cunningham
LCLinda Chang
Linda Chang
Objectives: We aimed to cross-sectionally and longitudinally compare brain morphometry and neuropsychiatric symptoms, and evaluate their relationship, in participants with Post-Coronavirus Disease Condition (PCC) and healthy Controls. Methods: At Baseline, 29 PCC (19 female; average age = 42.4 ± 12.2 years; 242 ± 156 days since infection) and 25 Controls (14 female; 44.1 ± 12.3 years) completed the NIH Toolbox Emotion, Motor and Cognition Batteries; Patient Reported Outcomes Measurement Information System (PROMIS); and structural brain MRI (thickness, areas, volumes). We compared neurobehavioral performance on the NIH Toolbox and PROMIS and structural brain morphometry for 34 cortical regions and 8 subcortical volumes, between PCC and matched Controls at Baseline (∼8 months post-infection) and 11 PCC and 7 Controls at a Follow-Up visit (∼3 years post-infection). Results: At Baseline, PCC had significantly larger putamen and amygdala (FDR-corrected p = 0.04; +5.3 and 5.9 %) and a trend for larger hippocampus and accumbens (uncorrected-p = 0.012 and 0.027, +5.1 and 12.9 %) than Controls. PCC also tended to have 4 thicker cortices (p = 0.010–0.049; +3.6–6.5 %), 6 larger surface areas (p = 0.009–0.023; +5.9–8.6 %), and 9 larger cortical volumes (p = 0.003–0.008; +4.2–10.7 %). These abnormal measures were associated with more anxiety, depression, and pain ( r = 0.5–0.75; p = 0.005–0.04). At Follow-Up, PCC had more sadness, fear, pain, and fatigue compared to Controls. However, group differences in morphometry diminished and PCC neurobehavioral performance tended to improve. Conclusions: Structural abnormalities in PCC suggest compensatory processes such as enhanced myelination or neurogenesis, rather than neuroinflammation, which in turn may contribute to persistent neurobehavioral symptoms. However, these alterations and symptoms may improve three years after infection.